Comparison · NCT01537042-sae
Rotigotine vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rotigotine vs Placebo: serious adverse events. Trial comparisons, record NCT01537042-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01537042-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.15 | 0.0524 | 0.36 | wilson | |
| Risk in group 2 | 0.1 | 0.0179 | 0.404 | wilson | |
| Risk difference, group 1 minus group 2 | 0.05 | -0.269 | 0.276 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.5 | 0.178 | 12.6 | log | |
| Odds ratio, group 1 over group 2 | 1.59 | 0.144 | 17.6 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Rotigotine than on Placebo | 20 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rotigotine | Rotigotine Transdermal Patch~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h. | 3 | 20 | EG001 |
| Group 2 | Placebo | Transdermal patch matched according to patch size and appearance.~Placebo: Transdermal patch; Patches matching to active treatment patches in size and appearance. | 1 | 10 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse Events were recorded during the course of the SP0934 study, which began in April 2012 and concluded in October 2013.
Source ClinicalTrials.gov
Trial
- Title
- A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
- NCT number
- NCT01537042
- Phases
- PHASE3
- Conditions
- Restless Legs Syndrome, End-Stage Renal Disease
- Interventions
- Rotigotine, Placebo
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Results first posted
- 2014-11-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01537042?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01537042-sae